An interventional study of HOPE-LC~Espanol in Post-Acute COVID-19 Syndrome, sponsored by Icahn School of Medicine at Mount Sinai. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-23.
Sponsored by Icahn School of Medicine at Mount Sinai · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Post-Acute COVID-19 Syndrome by Icahn School of Medicine at Mount Sinai — 6 open to participants now, 7 under way, 1 of them phase 3. Post-Acute COVID-19 Syndrome · Icahn School of Medicine at Mount Sinai.
Among the 10 studies in Post-Acute COVID-19 Syndrome by Icahn School of Medicine at Mount Sinai, this one is the 9th largest by planned enrollment, is one of 3 that started in 2026, is one of 6 with no phase, and was the 8th registered.
606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.
Browse Post-Acute COVID-19 Syndrome studies →6 of the 10 studies in Post-Acute COVID-19 Syndrome by Icahn School of Medicine at Mount Sinai are open now, in 1 country. Recruiting first, the newest first:
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18–65
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18+
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18+
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18+
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 16+
By country, each count listing its studies:
Of the 144 Post-Acute COVID-19 Syndrome studies recruiting now, 69 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 1
First in 2022; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 25 is below the median of 60 across 417 interventional studies indexed under Post-Acute COVID-19 Syndrome.
Median enrollment 45 across the 10 interventional studies. Of the 3 that completed or were terminated, 1 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
Icahn School of Medicine at Mount Sinai is the lead sponsor of 776 studies on the registry; 175 are open to participants now.
Of its 125 completed or terminated interventional studies of FDA-regulated products, 83 (66%) have results posted.
5 of the studies in Post-Acute COVID-19 Syndrome by Icahn School of Medicine at Mount Sinai that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06960928Phase 3Icahn School of Medicine at Mount SinaiLow Dose Sirolimus in People With Post-Acute Sequelae of COVID-19 (PASC) Long COVID-19 | 2026-12-31 |
| NCT06511063Icahn School of Medicine at Mount SinaiAntiviral Clinical Trial for Long Covid-19 | 2026-11 |
| NCT06511050Icahn School of Medicine at Mount SinaiLumbrokinase for Adults With Long Covid, Post-treatment Lyme Disease Syndrome, and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome | 2026-12 |
| NCT06585254Icahn School of Medicine at Mount SinaitVNS in Long COVID-19 | 2026-12-31 |
| NCT07600320Icahn School of Medicine at Mount SinaiFareon Open Label Device Clinical Trial | 2027-04-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 10 studies in Post-Acute COVID-19 Syndrome by Icahn School of Medicine at Mount Sinai, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The Harnessing Optimism and Perseverance in the Face of Long COVID (HOPE-LC) program, created by Drs. Eric Watson and Amelia Hicks, is a group therapy model designed to foster resilience, adjustment, and coping skills for those living with chronic Long COVID. HOPE-LC\~Español provides a culturally and linguistically adapted version for Spanish-speaking individuals in Queens, developed with input from Spanish-speaking clinicians, Long COVID experts, and people with lived experience. Partnering with H+H/Elmhurst and H+H/Queens, the project aims to recruit 25 participants and evaluate program feasibility and preliminary efficacy.
The Harnessing Optimism and Perseverance in the Face of Long COVID (HOPE-LC) program, developed by Drs. Eric Watson (PI) and Amelia Hicks (co-I), is a 12-week online group therapy program tailored specifically to living with Long COVID as a chronic condition. HOPE-LC provides community and hope; fostering resilience, adjustment, and critical coping strategies in the face of this debilitating chronic condition. Since its inception in 2024, the HOPE-LC groups have engaged 20 patients, emphasizing the need for chronic Long COVID therapeutic interventions.
Through HOPE-LC-Espanol the researchers will translate and adapt the HOPE-LC program into Spanish and expand HOPE-LC's reach to underserved Spanish-speaking communities in Queens and NYC. The aims are: (1) To translate and culturally adapt the HOPE-LC program for Spanish-speaking patients in collaboration with the Advisory Board of Spanish-speaking clinicians, Long COVID experts, and individuals with Long COVID lived experience; (2) In collaboration with the partners at H+H/Elmhurst and H+H/Queens, to conduct targeted recruitment to ensure the researchers are engaging specifically with local Hispanic/Latinx communities in Queens; and (3) To complete the HOPE-LC\~Español program for 25 Spanish-speaking individuals experiencing Long COVID within the local Queens community. The researchers will evaluate program feasibility and treatment success to inform future scalability and sustainability as a clinical program.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Spanish-speaking patients in the HOPE-LC program.
Behavioral: HOPE-LC~Espanol
12-week online group therapy program grounded in principles of Acceptance and Commitment Therapy and tailored specifically to living with Long COVID as a chronic condition. HOPE-LC provides community and hope; fostering resilience, adjustment, and critical coping strategies in the face of this debilitating chronic condition.
Recruitment rate
Number of eligible participants screened and enrolled by referral source
Time frame: Throughout the study period, 12 weeks
Retention rate
Number of participants completing the intervention (defined as attending at least 8 of 12 sessions)
Time frame: Throughout the study period, 12 weeks
Number of sessions participants attended
Feasibility measured via participant attendance
Time frame: Throughout the study period, 12 weeks
Number of completed surveys
Feasibility measured via number of surveys completed from participant follow-up and study procedures.
Time frame: Throughout the study period, 12 weeks
Patient Satisfaction
Post-treatment survey assessing participant satisfaction with HOPE-LC\~Español. Items are on a 5-point Likert Scale evaluated agreement to statements about their experience in the program (e.g., feeling heard, learning practical strategies, and willingness to recommend the program). The total score range is 5 - 40, with higher ratings indicating greater satisfaction.
Time frame: Post-treatment (Week 12)
DePaul Symptom Questionnaire
The DePaul Symptom Questionnaire (DSQ) is a validated tool to assess symptoms, frequency and severity of various symptoms of fatigue and other neurological impairment. Total score range 0-100, with higher scores indicating greater symptom severity and functional impairment.
Time frame: Baseline; 6 weeks, 12 weeks
Brief Illness Perception Questionnaire (BIPQ)
The BIPQ assesses cognitive and emotional representations of illness in 8 items + 1 open-ended causal item. Total score range is 0-80, higher scores mean a more negative perception of illness.
Time frame: Baseline; 6 weeks, 12 weeks
Valued Based Living Questionnaire (VLQ)
Assesses alignment between personal values and daily actions. Two ratings per domain: (1) Importance (1-10) and (2) Consistency with actions (1-10). Total score range is between 4-40. Higher consistency scores reflect greater valued living (better outcome); lower scores reflect minimal valued living (worse outcome).
Time frame: Baseline; 6 weeks, 12 weeks
Modified COVID-19 Yorkshire Rehabilitation Scale (C19-YRSm)
The C19-YRSm is a 17-item self-report scale designed to assess the impact of post-COVID symptoms. Items are rated on a scale from 0 (none of this symptom) to 3 (extremely severe level or impact). The scale includes four subscales: Symptom Severity (Questions 1-10; score range: 0-30) Functional Disability (Questions 11-15; score range: 0-15) Other Symptoms (Question 16; score range: 0-25) Overall Health (Question 17; score range: 0-10) Full scale from 0-80. Higher scores indicate greater symptom severity and functional impairment.
Time frame: Baseline; 6 weeks, 12 weeks
Patient Health Questionnaire-8 Item (PHQ-8)
Patient health questionnaire-8 (PHQ-8) is a multipurpose instrument for screening, diagnosing, monitoring and measuring the severity of depression. PHQ-8 is an 8-item instrument. Each question is rated on a scale of 0 to 3, total score scale from 0 - 24. Lower scores indicate minimal depression (better outcome) and higher scores indicate severe depression (worse outcome).
Time frame: Baseline; 6 weeks, 12 weeks
Generalized Anxiety Disorder-7 Item (GAD-7)
This is a 7-item measure that asks participants to rate the frequency with which they have been bothered by anxiety symptoms within the past two weeks on a scale ranging from 0 ("not at all") to 3 ("nearly every day"). Total scores range from 0-21, with higher scores indicating greater severity of generalized anxiety symptoms.
Time frame: Baseline; 6 weeks, 12 weeks
Plan to share: Yes — All of the individual participant data collected during the trial, after deidentification.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code
Time frame: Beginning 9 months and ending 36 months following article publication.
Access criteria: Researchers who provide a methodologically sound proposal. To achieve aims in the approved proposal. Proposals should be directed to eric.watson@mountsinai.org. To gain access, data requestors will need to sign a data access agreement. Data are available for 5 years at a third-party website (link to be determined).
No publications or documents are linked to this record.
Start is estimated for May 2026; primary completion for Aug 2026, 3 months later.
Of 232 non-industry interventional studies with no phase under Post-Acute COVID-19 Syndrome, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 28. This study's planned 3 months is below that.
Counting every sponsor, half of 243 studies reached it within 16 months; a quarter within 7 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Post-Acute COVID-19 Syndrome →
Icahn School of Medicine at Mount Sinai →